These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27881555)

  • 21. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
    Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.
    Duthoit G; Silvain J; Marijon E; Ducrocq G; Lepillier A; Frere C; Dimby SF; Popovic B; Lellouche N; Martin-Toutain I; Spaulding C; Brochet E; Attias D; Mansourati J; Lorgis L; Klug D; Zannad N; Hauguel-Moreau M; Braik N; Deltour S; Ceccaldi A; Wang H; Hammoudi N; Brugier D; Vicaut E; Juliard JM; Montalescot G
    Circ Cardiovasc Interv; 2020 Jul; 13(7):e008481. PubMed ID: 32674675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.
    Russo V; Rago A; Proietti R; Attena E; Rainone C; Crisci M; Papa AA; Calabrò P; D'Onofrio A; Golino P; Nigro G
    Biomed Res Int; 2019; 2019():5473240. PubMed ID: 30895193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
    Connolly SJ; Karthikeyan G; Ntsekhe M; Haileamlak A; El Sayed A; El Ghamrawy A; Damasceno A; Avezum A; Dans AML; Gitura B; Hu D; Kamanzi ER; Maklady F; Fana G; Gonzalez-Hermosillo JA; Musuku J; Kazmi K; Zühlke L; Gondwe L; Ma C; Paniagua M; Ogah OS; Molefe-Baikai OJ; Lwabi P; Chillo P; Sharma SK; Cabral TTJ; Tarhuni WM; Benz A; van Eikels M; Krol A; Pattath D; Balasubramanian K; Rangarajan S; Ramasundarahettige C; Mayosi B; Yusuf S;
    N Engl J Med; 2022 Sep; 387(11):978-988. PubMed ID: 36036525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis.
    Gong X; Tang S; Li J; Zhang X; Tian X; Ma S
    PLoS One; 2017; 12(10):e0186449. PubMed ID: 29023526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
    Cappato R; Ezekowitz MD; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca M; Vardas PE; Kirchhof P; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M; Hohnloser SH;
    Eur Heart J; 2014 Dec; 35(47):3346-55. PubMed ID: 25182247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS.
    Berwanger O; Wojdyla DM; Fanaroff AC; Budaj A; Granger CB; Mehran R; Aronson R; Windecker S; Goodman SG; Alexander JH; Lopes RD
    J Am Coll Cardiol; 2024 Sep; 84(10):875-885. PubMed ID: 39197976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation: A systematic review and meta-analysis of observational studies.
    Chaudhary N; Bundhun PK; Yan H
    Medicine (Baltimore); 2016 Dec; 95(50):e5581. PubMed ID: 27977592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
    Beyer-Westendorf J; Ehlken B; Evers T
    Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.